Fig. 1

Cell line characterization and monotherapy for eight TNBC and two control cell lines.

A and B show the efficiency of the 18 drugs on eight TNBC cell lines (BT-549, CAL-148, HCC1806, HCC38, HCC70, MDA-MB-436, MDA-MB-453, and MDA-MB-468) and two controls (MCF-10A and MCF-7) using growth rate inhibition (GR₅₀) and area under the curve (AUC). Bortezomib, carfilzomib, cisplatin, delanzomib, docetaxel, epoxomicin, MLN-2238, MLN-9708 and nedaplatin were shown to be potent drugs (GR₅₀ < 1000 nM and AUC < 0.80). C Scatterplot illustrating cytotoxicity with GR_max and GR₅₀ values. Topoisomerases were shown to be weak inhibitors, while proteasome inhibitors, mitosis inhibitors, and platinum agents had an adverse effect on cell viability. D and E show the cytotoxicity of all 18 drugs at the highest tested dose. The most cytotoxic drugs were celastrol, cisplatin, and nedaplatin, and the most sensitive cell lines to the highest dose were HCC38, HCC70, and MDA-MB-436. F show expression of AR in the 10 cell lines. Cell lines BT-549 (M), CAL-148 (LAR), HCC70 (BL1) and MDA-MB-453 (LAR) were AR-positive. Elevated AR expression was associated with high GR₅₀ values.